Sign in Subscribe
Cancer research

Improved Outcomes in Relapsed or Refractory Diffuse Large B-Cell Lymphoma with Polatuzumab Vedotin-Based Therapy

Strategic Insights

— 1 min read

A new report discusses the effectiveness of polatuzumab vedotin combined with rituximab and bendamustine in patients with relapsed or refractory diffuse large B-cell lymphoma. Research conducted at the Chiba Cancer Center Research Institute in Japan found that patients treated with this therapy showed improved overall survival rates and were more likely to achieve progression-free survival compared to those receiving conventional chemotherapy. This study suggests that polatuzumab vedotin-based therapy may be a more effective and tolerable treatment option for patients with this type of lymphoma.

Key Takeaways:

  • 86 patients with first relapse or primary refractory DLBCL were treated with either polatuzumab vedotin and rituximab and bendamustine (PBR) or conventional chemotherapy alone.
  • The median overall survival (OS) for all patients was 17.3 months, with the PBR-treated group showing significantly improved outcomes (median OS 19.7 vs. 15.8 months, P = 0.025).
  • Univariate and multivariate analyses identified PBR as a favorable prognostic factor for OS.
  • In the second-line setting, 41.2% of patients who received PBR were 80 years or older, compared with just 11.1% of those who received salvage regimens.
  • The PBR group showed a trend toward favorable progression-free survival despite the older age distribution.
  • The study concluded that PBR therapy is more effective and tolerable than conventional chemotherapy in patients with R/R DLBCL.

Statistics:

  • Median overall survival (OS) for all patients was 17.3 months.
  • Median OS for the PBR-treated group was 19.7 months and for the conventional chemotherapy group was 15.8 months.
  • Overall survival rate for the PBR-treated group was significantly higher than for the conventional chemotherapy group (P = 0.025).
  • 41.2% of patients who received PBR in the second-line setting were 80 years or older.
  • 11.1% of patients who received salvage regimens in the second-line setting were 80 years or older.

Sources:

  • "Efficacy of polatuzumab vedotin versus conventional chemotherapy in relapsed or refractory diffuse large B-cell lymphoma." International Journal of Hematology, 2025.
  • Chiba Cancer Center Research Institute, 666-2, Nitona-cho, Chuo-ku, Chiba, 260-8717, Japan.
  • Springer Japan Kk, Shiroyama Trust Tower 5F, 4-3-1 Toranomon, Minato-Ku, Tokyo, 105-6005, Japan. (www.springer.com; www.springerlink.com/content/0925-5710/)
  • Tatsuzo Mishina, Division of Hematology-Oncology, Chiba Cancer Center Research Institute.

Read more